If any more proof is needed, Trump's nomination of former Eli Lilly & Co.executive Alex Azar to become HHS secretary should confirm the Administration is not planning to take on the industry over drug pricing, despite the president's rhetoric.
Azar spent 10 years as an executive at the Big Pharma and is expected to be an even stronger industry...






